Crynodebau o Gyfarfodydd
C. Dayan. Immunotherapy in type 1 diabetes (Oral presentation). 54th EASD Annual Meeting, 2018.
O. Moser, M.L. Eckstein, A. Mueller, P. Birnbaumer, F. Aberer, G. Koehler, C. Sourij, H. Kojzar, P. Holler, H. Simi, P. Pferschy, P. Dietz, R.M. Bracken, P. Hofmann, H. Sourij. Reducing insulin degludec around regular exercise improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial. 54th EASD Annual Meeting, 2018.
J. Rafferty, A. Akbari, M.D. Atkinson, S.C. Bain, S. Luzio, J.W. Stephens, D.R. Owens, R.L. Thomas. Identifying all persons in Wales with type 1 diabetes mellitus using routinely collected linked data. International Population Data Linkage Network (IPDLN) Conference 2018.
H.A. Saevereid, M. Husain, S.C. Bain, J.F.E. Mann, M.A. Nauck, N. Poulter, B. Goldman, A.B. Thomsen, S. Marso, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effect of liraglutide on cardiovascular outcomes in patients with or without prior heart failure history in LEADER. 54th EASD Annual Meeting, 2018.
M. Husain, S.C. Bain, J.F.E. Mann, M.A. Nauck, N. Poulter, F.M.M. Baeres, B. Goldman, A.B. Thomsen, S. Marso, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Arrhythmias and heart rate increase in the LEADER trial and relation to risk of cardiovascular events. 54th EASD Annual Meeting, 2018.
C. Tack, S. Jacob, C. Desouza, S.C. Bain, M.A. Nauck, J. Petrie, N.R. Poulter, R.E. Pratley, H.B.K. Stegmann, H. Bosch-Traberg, E. Startseva, B. Zinman, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Liraglutide effects in insulin-treated patients in LEADER. 54th EASD Annual Meeting, 2018.
B. Zinman, S. Verma, D.L. Bhatt, S.C. Bain, J. Mann, M.A. Nauck, R.E. Pratley, M.M. Michelsen, T. Monk Fries, S. Rasmussen, L.A. Leiter, LEADER Publication Committee on behalf of the LEADER Trial Investigators. Effects of liraglutide on cardiovascular events in patients with type 2 diabetes and polyvascular disease: results of the LEADER trial. 54th EASD Annual Meeting, 2018.
S. Verma, S.C. Bain, T. Idorn, S. Rasmussen, D.D. Ørsted, M.A. Nauck, LEADER Publication Committee on behalf of the LEADER Trial Investigators. The cardiovascular benefits associated with liraglutide in the LEADER trial are sustained when analysing both first and recurrent MACE. 54th EASD Annual Meeting, 2018.
S. Bain, J. Frias, D. Gouet, R. Takács, T. Jia, P. Örsy, D. Sugimoto. Effects of IDegLira (insulin degludec/liraglutide) in patients with poorly controlled type 2 diabetes with HbA1c >9%: analyses from the DUAL programme. 54th EASD Annual Meeting, 2018.
E. Jódar, W. Polonsky, R. Réa, M. Warren, T. Vilsbøll, J. Håkan-Bloch, H. Vrazic, S. Lindberg, S.C. Bain. Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6). 54th EASD Annual Meeting, 2018.